Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The overall objective of the proposed study is to determine if Dexmedetomidine HCl (BXCL501)
is safe for treatment of alcohol use disorder (AUD) with comorbid posttraumatic stress
disorder (PTSD) and also shows potential signals of efficacy thereby supporting the conduct
of later phase clinical trials. Safety endpoints will be compared following an alcohol
challenge without and concurrent with BXCL501 treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Pharmacotherapies for Alcohol and Substance Abuse Consortium
Collaborators:
BioXcel Therapeutics Inc Congressionally Directed Medical Research Programs RTI International United States Department of Defense VA Connecticut Healthcare System Yale University